RUNX3 and neoplasm: The combination of RUNX3 and TP53 loss is frequently observed in human gastric cancer and is associated with particularly aggressive tumor behavior, genomic instability, and poor patient outcomes (Hsu et al., 2009; Wang N. et al., 2016).